Search

Displaying results 9961 - 9970 of 10000 in total
  1. Drug

    ZB131

    go.drugbank.com/drugs/DB17164
    Investigational

    ZB131 is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and

  2. Drug

    Ala-geninthiocin

    go.drugbank.com/drugs/DB15657
    Experimental

    Ala-geninthiocin is a novel thiopeptide antibacterial compound derived from marine _Streptomyces_ species. … [A192840] It has exhibited potent _in vitro_ activity against gram-positive bacteria including _Staphylococcus aureus_, _Bacillus subtilis_, _Mycobacterium smegmatis_, and _Micrococcus luteus_.

  3. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose

  4. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is designed for intravenous administration for acute use … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  5. Drug

    Zorecimeran

    go.drugbank.com/drugs/DB15843
    Investigational

    The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. … The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body.

  6. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety.

  7. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932). … The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in combination with a well-established

  8. Drug

    Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine

    go.drugbank.com/drugs/DB16431
    Experimental

    Receptor binding domain SARS-CoV-2 Hepatitis B surface antigen virus-like particle vaccine (RBD SARS-CoV-2 HBsAg VLP vaccine), is a virus-like particle vaccine candidate where the RBD antigen is conjugated … Regarding this vaccine specifically, it stimulates the immune system to produce anti-receptor binding domain antibodies[A226593].

  9. Drug

    beta-Alanine

    go.drugbank.com/drugs/DB03107
    Investigational

    beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].

  10. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973]